<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01352572</url>
  </required_header>
  <id_info>
    <org_study_id>2002-09-08</org_study_id>
    <nct_id>NCT01352572</nct_id>
  </id_info>
  <brief_title>Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients</brief_title>
  <official_title>Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether alteration of signal transduction
      components after antidepressant targeting, predict antidepressant responsiveness in advance
      before the appearance of the drug effects until 4~6 weeks after drug administration, or
      represent the clinical status of depressed patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether antidepressants effect on signal
      transduction in peripheral lymphocyte and to determine whether the signaling differences
      between drug responders and nonresponders predict the antidepressant response or represent
      the clinical status of depressed patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antidepressant Response at 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rsponse is defined as decrease rate of HAM-D score for 6week of treament is = or &gt;50%
Measurement Unit = responders, nonresponders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biological value at 0 and 6 weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>Biologial value is defined as protein expression value of signaling components in peripheral lymphocyte.
Measurement value : Optical Density(O.D), microgram/liter(ug/l)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>antidepressant response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>antidepressant response are refered the patients having a 50 â‰¤ Decrease rate(%) of HAM-D score</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antidepressant non-response</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antidepressant non-response are refered the patients having a 50 &gt; Decrease rate(%) of HAM-D score</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidepressant response</intervention_name>
    <description>Antidepressants administration for 6 weeks under therapeutic dose responders</description>
    <arm_group_label>antidepressant response</arm_group_label>
    <other_name>fluoxetine_Prozac</other_name>
    <other_name>paroxetine_Paxil, Seroxat</other_name>
    <other_name>sertraline_Zoloft</other_name>
    <other_name>milnacipran</other_name>
    <other_name>venlafaxine_Effexor</other_name>
    <other_name>nortriptyline_Aventyl, Pamelor, Noritren</other_name>
    <other_name>mirtazapine_Avanza, Zispin, Remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antidepressant non-response</intervention_name>
    <description>Antidepressants administration for 6 weeks under therapeutic dose nonresponders</description>
    <arm_group_label>antidepressant non-response</arm_group_label>
    <other_name>fluoxetine, paroxetine, sertraline</other_name>
    <other_name>milnacipran, venlafaxine, nortriptyline, mirtazapine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. met the Diagnostic and Statistical Manual of the American Psychiatric Association
             (DSM-IV) criteria for MDD from the Department of Psychiatry, Sungkyunkwan University,
             Seoul, South Korea.

          2. were 18 years of age or older, the existence of a unipolar major depressive episode as
             verified by DSM-III/IV criteria, at least 2 years after first episode onset, and
             agreement to informed consents

        Exclusion Criteria:

          -  pregnancy

          -  significant medical conditions

          -  abnormal laboratory baseline values

          -  unstable psychiatric features (e.g, suicidal attempt)

          -  history of alcohol or drug dependence, seizure, neurological illness, or concomitant
             Axis I psychiatric disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doh Kwan Kim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Kangnam</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>May 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2011</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Doh Kwan Kim</investigator_full_name>
    <investigator_title>M.D., pHD</investigator_title>
  </responsible_party>
  <keyword>Antidepressant Response</keyword>
  <keyword>Signal Transduction</keyword>
  <keyword>Lymphocyte</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Depressed Patients</keyword>
  <keyword>Antidepressant Drug Adverse Reaction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

